Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-04-29
DOI
10.3389/fphar.2021.614811
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors
- (2020) Naielly Rodrigues da Silva et al. PHARMACOLOGICAL RESEARCH
- From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases
- (2020) Tommaso Cassano et al. Frontiers in Pharmacology
- Relationship of negative symptom severity with cognitive symptoms and functioning in subjects at ultra‐high risk for psychosis
- (2020) Alp Üçok et al. Early Intervention in Psychiatry
- Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
- (2018) Philip McGuire et al. AMERICAN JOURNAL OF PSYCHIATRY
- In silico mapping of allosteric ligand binding sites in type-1 cannabinoid receptor
- (2018) Annalaura Sabatucci et al. BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY
- Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention
- (2018) F. Markus Leweke et al. CNS DRUGS
- Intellectual and cognitive profiles in patients affected by schizophrenia
- (2018) Margherita Bechi et al. Journal of Neuropsychology
- The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
- (2018) Douglas L. Boggs et al. PSYCHOPHARMACOLOGY
- Long-term cognitive trajectories and heterogeneity in patients with schizophrenia and their unaffected siblings
- (2018) Md. A. Islam et al. ACTA PSYCHIATRICA SCANDINAVICA
- Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors
- (2018) Andreza B. Sonego et al. BRAIN BEHAVIOR AND IMMUNITY
- Longitudinal Cognitive Changes in Young Individuals at Ultrahigh Risk for Psychosis
- (2018) Max Lam et al. JAMA Psychiatry
- Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis
- (2018) Sagnik Bhattacharyya et al. JAMA Psychiatry
- Remission of severe, treatment-resistant schizophrenia following adjunctive cannabidiol
- (2018) Christian Makiol et al. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
- Benzodiazepine long-term administration is associated with impaired attention/working memory in schizophrenia: results from the national multicentre FACE-SZ data set
- (2017) Guillaume Fond et al. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
- Speech graph analysis of verbal fluency tests distinguish between patients with schizophrenia and healthy controls
- (2017) A. Turek et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Cognitive clusters in first-episode psychosis: Overlap with healthy controls and relationship to concurrent and prospective symptoms and functioning.
- (2017) Jacqueline Uren et al. NEUROPSYCHOLOGY
- Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia
- (2017) Marco Aurélio Mori et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Placebo Response and Practice Effects in Schizophrenia Cognition Trials
- (2017) Richard S. E. Keefe et al. JAMA Psychiatry
- Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice
- (2016) Andreza B. Sonego et al. BEHAVIOURAL BRAIN RESEARCH
- Cannabidiol protects an in vitro model of the blood-brain barrier from oxygen-glucose deprivation via PPARγ and 5-HT1A receptors
- (2016) William H Hind et al. BRITISH JOURNAL OF PHARMACOLOGY
- Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo
- (2016) Lone Baandrup et al. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
- The dopamine D3 receptor, a quarter century later
- (2016) Pierre Sokoloff et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- Impact of avolition and cognitive impairment on functional outcome in first-episode schizophrenia-spectrum disorder: a prospective one-year follow-up study
- (2016) Wing Chung Chang et al. SCHIZOPHRENIA RESEARCH
- Association of Neurocognition With Transition to Psychosis
- (2016) Larry J. Seidman et al. JAMA Psychiatry
- Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence
- (2016) Cathrin Rohleder et al. Frontiers in Pharmacology
- Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor
- (2015) R B Laprairie et al. BRITISH JOURNAL OF PHARMACOLOGY
- Fatty Acid-binding Proteins (FABPs) Are Intracellular Carriers for Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)
- (2015) Matthew W. Elmes et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia
- (2014) G. Fervaha et al. ACTA PSYCHIATRICA SCANDINAVICA
- Neurocognitive Decrements are Present in Intellectually Superior Schizophrenia
- (2014) Anja Vaskinn et al. Frontiers in Psychiatry
- Anandamide Dysfunction in Prodromal and Established Psychosis
- (2012) F. Markus Leweke CURRENT PHARMACEUTICAL DESIGN
- Dopamine D2 Receptor Occupancy and Cognition in Schizophrenia: Analysis of the CATIE Data
- (2012) Hitoshi Sakurai et al. SCHIZOPHRENIA BULLETIN
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
- (2012) F M Leweke et al. Translational Psychiatry
- Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT1A somatodendritic autoreceptors in the dorsal raphe nucleus
- (2011) EM Rock et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cannabidiol Reduces Aβ-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPARγ Involvement
- (2011) Giuseppe Esposito et al. PLoS One
- Effects of cannabinoids and cannabinoid-enrichedCannabisextracts on TRP channels and endocannabinoid metabolic enzymes
- (2010) Luciano De Petrocellis et al. BRITISH JOURNAL OF PHARMACOLOGY
- Circumstances Under Which Practice Does Not Make Perfect: A Review of the Practice Effect Literature in Schizophrenia and Its Relevance to Clinical Treatment Studies
- (2010) Terry E Goldberg et al. NEUROPSYCHOPHARMACOLOGY
- Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)
- (2010) Jaime E. C. Hallak et al. REVISTA BRASILEIRA DE PSIQUIATRIA
- Neurocognition in first-episode schizophrenia: A meta-analytic review.
- (2009) Raquelle I. Mesholam-Gately et al. NEUROPSYCHOLOGY
- Relationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia
- (2008) Somaia Mohamed et al. AMERICAN JOURNAL OF PSYCHIATRY
- The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity
- (2008) Keith H. Nuechterlein et al. AMERICAN JOURNAL OF PSYCHIATRY
- Does stimulation of 5-HT1A receptors improve cognition in schizophrenia?
- (2008) Herbert Y. Meltzer et al. BEHAVIOURAL BRAIN RESEARCH
- Effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone
- (2008) Yu-Ting Wang et al. INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
- Cannabidiol for the treatment of psychosis in Parkinson’s disease
- (2008) AW Zuardi et al. JOURNAL OF PSYCHOPHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now